Subclinical thyrotoxicosis

Postgraduate Medical Journal

Volumn 77, Issue 903, 2001, Pages 29-32

  Al Abadi, A G ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE SEVERITY; HUMAN; LIOTHYRONINE BLOOD LEVEL; PATHOPHYSIOLOGY; REVIEW; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; HYPERTHYROIDISM; OSTEOPOROSIS; RISK FACTORS; THYROTOXICOSIS; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0035181898     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.77.903.29     Document Type: Review

References (53)

1. Application of a new chemiluminometric thyrotropin assay to subnormal measurement
2. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays
3. Comparison between TRH-stimulated TSH and basal TSH measurement by a commercial immunoradiometric assay in the management of thyroid disease
4. Comparison of serum thyrotrophin concentrations determined by a third generation assay in patients with various types of overt and subclinical thyrotoxicosis
5. The metabolism of thyroid hormones. 2. Detection of thyroxine and triiodothyronine in human plasma
6. Free triiodothyronine toxicosis: A distinct entity
7. Asian women are at increased risk of gestational thyrotoxicosis
8. Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice
9. 3) toxicosis
10. The significance of TSH values measured in a sensitive assay in the follow-up of hyperthyroid patients treated with radioiodine
11. Thyrotropin results in euthyroid patients with a past history of hyperthyroidism
12. The many causes of subclinical hyperthyroidism
13. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities
14. Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism
15. Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with non-toxic nodular goitre
16. Screening for thyroid disease in a primary care unit with a thyroid-stimulating hormone assay with a low detection limit
17. Thyroid dysfunction in adults over age 55 years. A study in an urban US community
18. Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom
19. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham survey
20. Sensitive thyrotropin and free thyroxine testing in outpatients: Are both necessary?
21. The natural history of euthyroid multinodular goitre
22. Subclinical Graves' disease as a cause of subnormal TSH levels in euthyroid subjects
23. Iodine-induced hyperthyroidism: Occurrence and epidemiology
24. High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment
25. Thyrotoxicosis and the heart
26. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons
27. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study
28. How useful is thyroid function testing in patients with reccnt-onset atrial fibrillation?
29. Diastolic dysfunction in patients on thyroid-stimulating hormone Suppressive therapy with levothyroxine: Beneficial effect of β-blockade
30. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine
31. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine
32. Negative correlation between the changes in bone mineral density and serum osteocalcin in patients with hyperthyroidism
33. Mineral and bone metabolism in thyroid disease: A review
34. A therapeutic dilemma: Suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma
35. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis
36. Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH
37. Long-term thyroxine treatment and bone mineral density
38. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy
39. Morbidity in patients on L-thyroxine: A comparison of those with a normal TSH to those with a suppressed TSH
40. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid replacement
41. Circulating lipids and minor abnormalities of thyroid function
42. Variations of sex hormone-binding globulin in thyroid dysfunction
43. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine
44. Subclinical hyperthyroidism: Physical and mental state of patients
45. Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism
46. A new chemiluminescent assay for the rapid detection of thyroid stimulating antibodies in Graves' disease
47. Geographical distribution of subclinical autoimmune thyroid disease in Britain: A study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase
48. Control of adrenergic overactivity by β-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine
49. Significant reversal of thyrotoxicosis-associated dilated cardiomyopathy with induction of the euthyroid state
50. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy
51. Thyroid hormone use and bone mineral density in elderly women: Effect of estrogen
52. Bone metabolism during antithyroid drug treatment of endogenous subclinical hyperthyroidism
53. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans